Powles T, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). ASCO-GU 2019, abstract 545.
CD44 en MET, partners in carcinogenese van CRC
okt 2021 | Maag-darm-leveroncologie